Online inquiry

IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11224MR)

This product GTTS-WQ11224MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets pcrV&psl gene. The antibody can be applied in P. Aeruginosa nosocomial pneumonia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11224MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8716MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ11187MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ5505MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ3560MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ10367MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ3250MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ15345MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ12086MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW